The Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies has awarded a contract valued at $27.3 million to Ology Bioservices a biologics CDMO.
The contract with the US-based company is to establish their proprietary Veroplex cell platform for rapid response to emerging viral diseases.
Peter Khoury, President and CEO of Ology Bioservices, said: "The Veroplex platform has the possibility to allow rapid vaccine development for many potential emerging viral infectious diseases."
Khoury explained: "There is solid evidence that this Vero cell line, when combined with recent innovations in vaccine manufacturing technology, may be valuable in quickly manufacturing vaccines and other biologics in a very small footprint."
